Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Identification of individuals with tuberculosis for antibiotic treatment is a major component of the of WHO's End TB Strategy. Diagnostic tests for tuberculosis rely on detection of Mycobacterium tuberculosis in sputum expectorated by a person with productive cough. The search for new sputum-independent diagnostic tests is gaining momentum, as exemplified by advances in urine-based point-of-care lipoarabinomannan lateral flow assays for use in hospitalised patients with HIV.

More information Original publication

DOI

https://doi.org/10.1016/S2213-2600(19)30355-8

Type

Alumni publications

Publisher

The Lancet

Publication Date

01/04/2020

Volume

8

Keywords

antibiotic treatment, Tuberculosis, cough , sputum-independent diagnostic test